Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Passage Bio (PASG)
NASDAQ:PASG
Holding PASG?
Track your performance easily
PASG Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.45 - $1.79
Previous Close$0.51
Volume994.92K
Average Volume (3M)250.29K
Market Cap
$31.19M
Enterprise Value-$27.82M
Total Cash (Recent Filing)$84.83M
Total Debt (Recent Filing)$25.82M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Feb 27, 2025EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding61,767,286
10 Day Avg. Volume270,666
30 Day Avg. Volume250,295
Standard Deviation0.22
R-Squared0.08
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.43
Price to Sales (P/S)51.78
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-48.37
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.41
Forecast
1Y Price Target
$10.00Price Target Upside1510.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Passage Bio News
PremiumCompany Announcements
Passage Bio Shows Progress in Gene Therapy Trials
PremiumCompany Announcements
Passage Bio Achieves Milestones in Gene Therapy Trials
PremiumCompany Announcements
Passage Bio Presents Promising Data on PBFT02 Therapy
PremiumCompany Announcements
Passage Bio Reveals Promising Gene Therapy Trial ResultsOwnership Overview
12.79% Insiders
4.96% Mutual Funds
51.69% Other Institutional Investors
27.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PASG FAQ
What was Passage Bio’s price range in the past 12 months?
Passage Bio lowest stock price was $0.45 and its highest was $1.79 in the past 12 months.
What is Passage Bio’s market cap?
Currently, no data Available
When is Passage Bio’s upcoming earnings report date?
Passage Bio’s upcoming earnings report date is Feb 27, 2025 which is in 93 days.
How were Passage Bio’s earnings last quarter?
Passage Bio released its earnings results on Nov 13, 2024. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.232 by -$0.078.
Is Passage Bio overvalued?
According to Wall Street analysts Passage Bio’s price is currently Undervalued.
Does Passage Bio pay dividends?
Passage Bio does not currently pay dividends.
What is Passage Bio’s EPS estimate?
Passage Bio’s EPS estimate is -$0.22.
How many shares outstanding does Passage Bio have?
Passage Bio has 61,767,284 shares outstanding.
What happened to Passage Bio’s price movement after its last earnings report?
Passage Bio reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.232. Following the earnings report the stock price went down -13.433%.
Which hedge fund is a major shareholder of Passage Bio?
Among the largest hedge funds holding Passage Bio’s share is New Leaf Venture Partners, L.L.C.. It holds Passage Bio’s shares valued at 2M.
---
Passage Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (1510.31% Upside)
$10.00 (1510.31% Upside)
Blogger Sentiment
Bullish
PASG Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 4.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $174.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.61%
12-Months-Change
Fundamentals
Return on Equity
-69.15%
Trailing 12-Months
Asset Growth
-33.97%
Trailing 12-Months
Company Description
Passage Bio
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
---
PASG Company Deck
---
PASG Earnings Call
Q4 2023
0:00 / 0:00
---
PASG Stock 12 Month Forecast
Average Price Target
$10.00
▲(1510.31% Upside)
Technical Analysis
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Editas Medicine
―
Best Analysts Covering PASG
1 Year
1 Year Success Rate
3/12 ratings generated profit
1 Year Average Return
-29.28%
reiterated a buy rating 11 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -29.28% per trade.
---